The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro developments. As such, investors are taking notice and bidding up shares.

But not every company with momentum is a long-term winner, and plenty of investors have lost money betting on short-term fads. Keeping that in mind, here are three overhyped stocks that may correct and some you should consider instead.

ArcBest (ARCB)

One-Month Return: +16.7%

Historically owning furniture, banking, and other subsidiaries, ArcBest (NASDAQ: ARCB) offers full-truckload, less-than-truckload, and intermodal deliveries of freight.

Why Do We Think ARCB Will Underperform?

1. Customers postponed purchases of its products and services this cycle as its revenue declined by 4.8% annually over the last two years
2. Earnings per share decreased by more than its revenue over the last two years, showing each sale was less profitable
3. Waning returns on capital imply its previous profit engines are losing steam

ArcBest’s stock price of $109.25 implies a valuation ratio of 23.1x forward P/E. Dive into our free research report to see why there are better opportunities than ARCB.

STAAR Surgical (STAA)

One-Month Return: +46.1%

With over 2.5 million implants performed worldwide, STAAR Surgical (NASDAQ: STAA) designs and manufactures implantable lenses that correct vision problems without removing the eye's natural lens.

Why Is STAA Risky?

1. Sales tumbled by 13.8% annually over the last two years, showing market trends are working against its favor during this cycle
2. Free cash flow margin dropped by 29.9 percentage points over the last five years, implying the company became more capital intensive as competition picked up
3. Eroding returns on capital from an already low base indicate that management’s recent investments are destroying value

STAAR Surgical is trading at $25.17 per share, or 36x forward P/E. Read our free research report to see why you should think twice about including STAA in your portfolio.

Flex (FLEX)

One-Month Return: +23.3%

Originally known as Flextronics until its 2016 rebranding, Flex (NASDAQ: FLEX) is a global manufacturing partner that designs, engineers, and builds products for companies across industries from medical devices to solar trackers.

Why Are We Hesitant About FLEX?

1. Products and services are facing end-market challenges during this cycle, as seen in its flat sales over the last two years
2. Poor free cash flow margin of 2.8% for the last five years limits its freedom to invest in growth initiatives, execute share buybacks, or pay dividends
3. Diminishing returns on capital suggest its earlier profit pools are drying up

At $75.09 per share, Flex trades at 20.8x forward P/E. To fully understand why you should be careful with FLEX, check out our full research report (it’s free).

Stocks We Like More

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it's flagging for this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.